Dose-Ranging Study Evaluating AVE1625 in Abdominally Obese Patients With Atherogenic Dyslipidemia

Inclusion Criteria: Abdominal obese patients with · Waist circumference > 102 cm in men and >88 cm in women Dyslipidemia consisting of : Triglycerides ≥ 1.50 g/L (i.e 1.69 mmol/L) and ≤ 7.0 g/L(i.e. 7.90 mmol/L)AND/OR HDL-cholesterol < 50 mg/dL (i.e. 1.29 mmol/L) in women and < 40 mg/dL (i.e. 1.04 mmol/L) in men Exclusion Criteria: Pregnancy or lactation Women of child-bearing potential with no medically approved contraception Patients with type 1 diabetes Patients with type 2 diabetes must be on a stable dose of oral antidiabetic drugs (excluding glitazones, exenatide, sulfonylurea and nateglinide) and should not receive insulin therapy Patients with any clinically significant endocrine disease Patients on anticoagulants (heparin, warfarin) or with bleeding disorders Clinically relevant disease interfering with subject's safety or making implementation of the study protocol or interpretation of study results difficult Patients with mental retardation or any clinically significant psychiatric disorder History or concurrent substance abuse (other than nicotine or caffeine especially marijuana or hashish) Chronic systemic corticotherapy Patients with weight change > 5kg within 3 months prior to screening Patients should not have received anti-obesity drugs or other drugs for weight reduction in the 3 months prior to screening. The investigator will evaluate whether there are other reasons why a patient may not participate